share_log

Baird Maintains Outperform on Larimar Therapeutics, Lowers Price Target to $10

Benzinga ·  Mar 25 11:39

Baird analyst Joel Beatty maintains Larimar Therapeutics (NASDAQ:LRMR) with a Outperform and lowers the price target from $13 to $10.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 242

Recommended

Write a comment